Clinical-Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma.
BRAF
PTC
RET/PTC
TERT
hobnail variant
papillary thyroid carcinoma
treatment outcome
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
12
2021
accepted:
07
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Papillary thyroid carcinoma (PTC) with hobnail areas above 30% is classified as hobnail variant (HVPTC). Although it is widely accepted that HVPTC has a worse outcome than classical PTC, it is unclear whether PTC with hobnail features below 30% is as aggressive as HVPTC. We gathered the largest mono-institutional series of PTC with hobnail areas and HVPTC to evaluate differences in terms of pathological features of aggressiveness, molecular profile, and treatment outcome. A total of 99 PTC with hobnail features above 5% were retrospectively selected; 34 of them met the criteria for HVPTC (0.4% of all PTC diagnosed at our institution). All tumors showed high rates of extra-thyroidal extension (40.4%), lymph node metastasis (68.1% of patients with lymphadenectomy), and vascular emboli (49.5%), with no differences according to the 30% cutoff. On the other hand, distant metastases were present in HVPTC only (9.4%). Also, advanced age, advanced disease stage, and
Identifiants
pubmed: 35311230
doi: 10.3389/fendo.2022.842424
pmc: PMC8926070
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
842424Informations de copyright
Copyright © 2022 Poma, Macerola, Proietti, Vignali, Sparavelli, Torregrossa, Matrone, Basolo, Elisei, Santini and Ugolini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocrine. 2021 Apr;72(1):27-39
pubmed: 33025563
Histopathology. 2018 Jan;72(1):40-52
pubmed: 29239042
Endocr Relat Cancer. 2018 Mar;25(3):L7-L11
pubmed: 29192093
Endocrine. 2014 Aug;46(3):363-4
pubmed: 24615658
J Clin Pathol. 2004 Oct;57(10):1041-6
pubmed: 15452157
Adv Anat Pathol. 2018 May;25(3):172-179
pubmed: 29351089
Thyroid. 2018 Jan;28(1):96-103
pubmed: 29179638
Thyroid. 2018 Oct;28(10):1301-1310
pubmed: 30141373
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Int J Clin Exp Pathol. 2015 Jul 01;8(7):7988-97
pubmed: 26339365
Endocrine. 2020 Mar;67(3):623-629
pubmed: 31776976
Endocr Relat Cancer. 2017 Feb;24(2):107-117
pubmed: 28062544
Thyroid. 2017 Nov;27(11):1408-1416
pubmed: 28891405
Ann Surg Oncol. 2017 Sep;24(9):2611-2616
pubmed: 28585075
Endocrine. 2014 Aug;46(3):532-7
pubmed: 24287799
Am J Surg Pathol. 2010 Jan;34(1):44-52
pubmed: 19956062
Diagn Cytopathol. 2014 Jan;42(1):78-84
pubmed: 23913779
Am J Surg Pathol. 2015 Feb;39(2):260-5
pubmed: 25321328
Medicine (Baltimore). 2018 Jul;97(29):e11548
pubmed: 30024548
Endocrine. 2020 Jun;68(3):607-616
pubmed: 32124258
Virchows Arch. 2015 Aug;467(2):177-84
pubmed: 26055532
Oncotarget. 2017 Mar 28;8(13):22023-22033
pubmed: 28423545
Cancers (Basel). 2021 Oct 29;13(21):
pubmed: 34771585
Hum Pathol. 2013 Mar;44(3):320-8
pubmed: 23036367
Thyroid. 2014 Jun;24(6):958-65
pubmed: 24417340